MS4A1 and B-cell non-Hodgkin lymphoma: Given the high specificity of CD20 and the success Rituximab had, a number of other monoclonal antibodies were developed and are currently used in the UK in the treatment of B-cell lymphomas and leukaemia that are refractory to the first-line treatment with rituximab or in patients were first line treatment is not possible.